Eric W. Thomas

Array ( [id] => 11689606 [patent_doc_number] => 20170165321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'METHOD FOR REDUCING AND/OR DELAYING PATHOLOGICAL EFFECTS OF HUMAN IMMUNODEFICIENCY VIRUS I (HIV) OR FOR REDUCING THE RISK OF DEVELOPING ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)' [patent_app_type] => utility [patent_app_number] => 15/325131 [patent_app_country] => US [patent_app_date] => 2015-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 24445 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177463 [patent_doc_number] => 20180036400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'DOUBLE ENGINEERED HIV-1 ENVELOPES' [patent_app_type] => utility [patent_app_number] => 15/320432 [patent_app_country] => US [patent_app_date] => 2015-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 3194 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15320432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476143 [patent_doc_number] => 20150361160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'BROADLY NEUTRALIZING ANTIBODY AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/731621 [patent_app_country] => US [patent_app_date] => 2015-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 21496 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14731621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17201394 [patent_doc_number] => 20210341489 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-11-04 [patent_title] => METHOD AND COMPOSITION FOR DETERMINING SPECIFIC ANTIBODY RESPONSES TO SPECIES OF FILOVIRUS [patent_app_type] => utility [patent_app_number] => 15/316020 [patent_app_country] => US [patent_app_date] => 2015-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15316020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17201394 [patent_doc_number] => 20210341489 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-11-04 [patent_title] => METHOD AND COMPOSITION FOR DETERMINING SPECIFIC ANTIBODY RESPONSES TO SPECIES OF FILOVIRUS [patent_app_type] => utility [patent_app_number] => 15/316020 [patent_app_country] => US [patent_app_date] => 2015-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15316020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10380693 [patent_doc_number] => 20150265700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'POLYVALENT VACCINE' [patent_app_type] => utility [patent_app_number] => 14/726373 [patent_app_country] => US [patent_app_date] => 2015-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 109 [patent_no_of_words] => 13269 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14726373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555215 [patent_doc_number] => 20170101461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'Antiretroviral Drug Targeting Human Endogenous Retrovirus' [patent_app_type] => utility [patent_app_number] => 15/314017 [patent_app_country] => US [patent_app_date] => 2015-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13589 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15314017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11127990 [patent_doc_number] => 20160324965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS' [patent_app_type] => utility [patent_app_number] => 14/706910 [patent_app_country] => US [patent_app_date] => 2015-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14732 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14706910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10461200 [patent_doc_number] => 20150346215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'FILOVIRUS FUSION PROTEINS AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/704792 [patent_app_country] => US [patent_app_date] => 2015-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14940 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14704792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12247346 [patent_doc_number] => 09920111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity' [patent_app_type] => utility [patent_app_number] => 14/692483 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 74 [patent_no_of_words] => 54071 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11276061 [patent_doc_number] => 09492532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Nucleic acids encoding mosaic HIV-1 gag proteins' [patent_app_type] => utility [patent_app_number] => 14/689957 [patent_app_country] => US [patent_app_date] => 2015-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 28 [patent_no_of_words] => 9615 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14689957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12043470 [patent_doc_number] => 09821053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins' [patent_app_type] => utility [patent_app_number] => 14/689995 [patent_app_country] => US [patent_app_date] => 2015-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 46 [patent_no_of_words] => 13450 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14689995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568615 [patent_doc_number] => 20170107260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'MOSAIC HIV-1 SEQUENCES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/127986 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8305 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15127986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10533817 [patent_doc_number] => 09259433 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-16 [patent_title] => 'Synergistic antiviral compositions comprising a viral attachment inhibitor, an integration inhibitor, and a proviral transcription inhibitor, and their use' [patent_app_type] => utility [patent_app_number] => 14/641727 [patent_app_country] => US [patent_app_date] => 2015-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 25 [patent_no_of_words] => 10185 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14641727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336723 [patent_doc_number] => 20160362479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region' [patent_app_type] => utility [patent_app_number] => 15/121051 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23091 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15121051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714896 [patent_doc_number] => 20170183396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'EBOLA MONOCLONAL ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/120245 [patent_app_country] => US [patent_app_date] => 2015-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17091 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10262390 [patent_doc_number] => 20150147387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'METHOD OF INDUCING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS INVOLVING THE ADMINISTRATION OF MPER PEPTIDE-LIPOSOME CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/612665 [patent_app_country] => US [patent_app_date] => 2015-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 11042 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14612665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883553 [patent_doc_number] => 10421803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits [patent_app_type] => utility [patent_app_number] => 15/115547 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 60 [patent_no_of_words] => 19482 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15115547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15006279 [patent_doc_number] => 10449245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent [patent_app_type] => utility [patent_app_number] => 15/114296 [patent_app_country] => US [patent_app_date] => 2015-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20689 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270513 [patent_doc_number] => 20160333060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ANTI-VIRAL CNIDARINS' [patent_app_type] => utility [patent_app_number] => 15/110156 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24415 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110156 [rel_patent_id] =>[rel_patent_doc_number] =>)